Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Wantong Yao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-0172-7530; OpenAlex author ID A5019378272; NIH RePORTER profile ID 14127043. Sources: funder_awards.

Their work

Papers
26 (first author 2, last author 2)
Trials
0
Grants
5
Labs led
1
Collaborators
84
Papers, trials and grants by year

2012: 2 papers · 2013: 3 papers · 2014: 3 papers · 2015: 1 paper · 2016: 1 paper, 1 grant · 2017: none · 2018: none · 2019: 4 papers, 1 grant · 2020: 2 papers · 2021: 2 papers · 2022: none · 2023: none · 2024: 1 paper · 2025: 1 paper, 1 grant · 2026: 6 papers, 2 grants

Papers 26

  1. Syndecan-1-targeted therapeutic antibody impairs macropinocytosis and elicits antitumor immunity in pancreatic cancer. Last author DOI 10.1016/j.xcrm.2026.102613↗
  2. All-trans retinoic acid destabilizes ADAR1 protein through retinoylation-mediated USP7 dissociation and improves immunotherapy in pancreatic cancer. Co-author DOI 10.1038/s41467-026-72271-5↗
  3. Author Correction: Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Co-author DOI 10.1038/s41586-026-10488-6↗
  4. Syndecan-1 Is a Key Mediator of Entosis and Cellular Competition in Pancreatic Cancer. Last author DOI 10.1097/mpa.0000000000002542↗
  5. GFER Represents a Target for Dual Disruption of Redox Homeostasis and Reactivation of the Immune Response in Pancreatic Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-24-4211↗
  6. DPY30 Is an Epigenetic Decoupler Linking Replication Stress to Immunoediting in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-3849↗
  7. KRAS Inhibition Activates an Actionable CD24 "Do Not Eat Me" Signal in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-2024↗
  8. WRAD core perturbation impairs DNA replication fidelity promoting immunoediting in pancreatic cancer Co-author DOI 10.1101/2024.10.21.619543↗
  9. USP21 deubiquitinase elevates macropinocytosis to enable oncogenic KRAS bypass in pancreatic cancer. Co-author DOI 10.1101/gad.348787.121↗
  10. Targeting Glucose Metabolism Sensitizes Pancreatic Cancer to MEK Inhibition. Co-author DOI 10.1158/0008-5472.can-20-3792↗
  11. Recent insights into the biology of pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2020.102655↗
  12. Diversity Across the Pancreatic Ductal Adenocarcinoma Disease Spectrum Revealed by Network-Anchored Functional Genomics Co-author DOI 10.1101/2020.09.17.302034↗
  13. Hear Pancreatic Cancer Stem Cells ROR. Co-author DOI 10.1016/j.cell.2019.04.002↗
  14. Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. Co-author DOI 10.1038/s41586-019-1062-1↗
  15. YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma. Co-author DOI 10.1172/jci.insight.130811↗
  16. Glucose Metabolism in Pancreatic Cancer. Co-author DOI 10.3390/cancers11101460↗
  17. In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer. Co-author DOI 10.1016/j.celrep.2016.05.063↗
  18. Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer. Co-author DOI 10.1158/0008-5472.can-14-1854↗
  19. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. First author DOI 10.1016/j.cell.2014.06.003↗
  20. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Co-author DOI 10.1038/nature13611↗
  21. Profilin-1 suppresses tumorigenicity in pancreatic cancer through regulation of the SIRT3-HIF1α axis. Co-author DOI 10.1186/1476-4598-13-187↗
  22. Up-regulation of MBD1 promotes pancreatic cancer cell epithelial-mesenchymal transition and invasion by epigenetic down-regulation of E-cadherin. Co-author DOI 10.2174/1566524011313030008↗
  23. Gene profile identifies zinc transporters differentially expressed in normal human organs and human pancreatic cancer. Co-author DOI 10.2174/1566524011313030009↗
  24. Silencing of MBD1 reverses pancreatic cancer therapy resistance through inhibition of DNA damage repair. Co-author DOI 10.3892/ijo.2013.1901↗
  25. Combinational therapy: new hope for pancreatic cancer? First author DOI 10.1016/j.canlet.2011.11.029↗
  26. RGD-conjugated albumin nanoparticles as a novel delivery vehicle in pancreatic cancer therapy. Co-author DOI 10.4161/cbt.13.4.18692↗

Grants 5

  1. A Novel Cell Stress Response Mechanism in Pancreatic Cancer R01CA308198↗
  2. Targeting Acquired Resistance in KRAS Driven Cancers R37CA272744↗
  3. A Novel Strategy of Targeting Transmembrane Protein to Improve KRAS-targeted Therapy R21CA288804↗
  4. Targeting Syndecan1 in Pancreatic Cancer AWARD pancan:2019-wantong-yao-md-phd-targeting-syndecan1-in-pancreatic-cancer
  5. Syndecan-1 is a Novel Regulator for Nutrient Salvage Pathway AWARD pancan:2016-wantong-yao-md-phd-syndecan-1-is-a-novel-regulator-for-nutr

Closest collaborators

The 25 strongest of 84 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Haoqiang Ying · 13 shared papers, 2014–2026 · strength 1.66
  2. Timothy Paul Heffernan · 13 shared papers, 2014–2026 · strength 1.35
  3. Giulio Francesco Draetta · 12 shared papers, 2014–2026 · strength 1.28
  4. Huamin Wang · 11 shared papers, 2014–2026 · strength 1.23
  5. Andrea Viale · 11 shared papers, 2014–2026 · strength 1.17
  6. Giannicola Genovese · 8 shared papers, 2014–2026 · strength 0.91
  7. Alessandro Carugo · 9 shared papers, 2014–2026 · strength 0.86
  8. Anirban Maitra · 7 shared papers, 2016–2026 · strength 0.85
  9. Ronald Anthony Depinho · 8 shared papers, 2014–2026 · strength 0.67
  10. I-Lin Ho · 5 shared papers, 2019–2026 · strength 0.67
  11. Yongkun Wei · 3 shared papers, 2025–2026 · strength 0.60
  12. Ziheng Chen · 4 shared papers, 2019–2026 · strength 0.58
  13. Virginia Giuliani · 5 shared papers, 2014–2026 · strength 0.58
  14. Jason B. Fleming · 7 shared papers, 2014–2026 · strength 0.54
  15. Francesca Citron · 3 shared papers, 2024–2026 · strength 0.52
  16. Yan Liang · 5 shared papers, 2019–2021 · strength 0.48
  17. Ya’an Kang · 5 shared papers, 2014–2026 · strength 0.44
  18. Jun Yao · 4 shared papers, 2019–2025 · strength 0.41
  19. Piergiorgio Pettazzoni · 6 shared papers, 2014–2026 · strength 0.39
  20. Johnathon Lynn Rose · 4 shared papers, 2016–2026 · strength 0.39
  21. Ching-Fei Li · 2 shared papers, 2025–2026 · strength 0.38
  22. Avnish Kapoor · 5 shared papers, 2014–2026 · strength 0.35
  23. Alec C. Kimmelman · 3 shared papers, 2014–2026 · strength 0.34
  24. Kara Z. Li · 1 shared paper, 2026 · strength 0.32
  25. Christine A. Iacobuzio–Donahue · 1 shared paper, 2026 · strength 0.32

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.